NDAOPHTHALMICOINTMENT1 Generic Approved
Approved
Jul 1963
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Data completeness
5/8 — Partial
MAXITROL (neomycin sulfate, polymyxin b sulfate and dexamethasone) by Novartis is corticosteroid hormone receptor agonists [moa]. Approved for corticosteroid [epc]. First approved in 1963.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXITROL is a fixed-dose combination ophthalmic ointment containing neomycin sulfate, polymyxin B sulfate, and dexamethasone, approved in 1963. It is a topical corticosteroid with broad-spectrum antibiotic coverage used to treat ocular inflammation and bacterial infections of the eye. The dexamethasone component acts as a corticosteroid hormone receptor agonist to reduce inflammation, while the antibiotics provide bacterial coverage.
$0.003BPart D
LOE ApproachingDeclining
MAXITROL faces declining market presence approaching loss of exclusivity with minimal current commercial investment and limited competitive differentiation in a crowded ophthalmic corticosteroid space.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAXITROL offers limited career growth due to its LOE-approaching status, minimal current spending ($3K in Part D claims), and zero linked job postings, indicating a skeleton team focused on harvest management rather than expansion. Professionals joining this franchise should expect a defensive, operational posture centered on margin protection and generic transition rather than market expansion or innovation.
Brand Manager (legacy product management)
Worked on MAXITROL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.